Brief: Simcere Pharmaceutical's Unit Enters Into License Agreement With Nextcure
16/06/2025 14:11
June 16 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK: UNIT ENTERED INTO A LICENSE AGREEMENT WITH NEXTCURE PURSUANT TO LICENSE AGREEMENT, GROUP ELIGIBLE TO RECEIVE PAYMENTS UP TO US$745 MILLION UNDER DEAL NEXTCURE TO OBTAIN GLOBAL RIGHTS TO SIM0505 NOVEL ANTIBODY-DRUG CONJUGATE, OTHERS Further company coverage: 2096.HK ((Reuters.Briefs@thomsonreuters.com))
Recent news on NextCure
See all newsBrief: Xcellon Biologics Co Acquires Gmp Manufacturing Facility From Nextcure
NextCure Inc reports results for the quarter ended June 30 - Earnings Summary
NextCure Q2 net loss narrows on lower expenses
Brief: NextCure Q2 Net Income USD -14.892 Million
NextCure Inc expected to post a loss of $1.93 a share - Earnings Preview